New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
16:28 EDTINO, VRX, EBAY, EHTH, AGN, RCPT, COUP, FBOn The Fly: Closing Wrap
Stocks on Wall Street began the day slightly below the flat line and remained there for most of the session, before a late move higher allowed the Dow to run its recent winning streak to another day, though just barely. Economic reports from at home and abroad, which included wholesale trade data in the U.S. and inflation data from China, had little effect on the market, which seemed content to spend the session drifting. The Dow and S&P 500 stand just short of major round-number milestones, but both will have to wait at least another day to see if they can be reached. ECONOMIC EVENTS: In the U.S., wholesale inventories rose 1.1% in April, with sales up 1.3%, which were both better than forecast. The JOLTS report showed job openings climbed 289K to 4.46M in April. In China, official data showed an index of consumer prices rose 2.5% year-on-year in May, while China's producer price index contracted 1.4% during the month. COMPANY NEWS: Shares of eBay (EBAY) closed down $1.33, or 2.68%, to $48.25 after the company announced last night that PayPal President David Marcus is leaving the company to lead Facebook’s (FB) messaging products. Facebook shares reacted positively to the executive hiring, rising $2.89, or 4.6%, to $65.77... Allergan (AGN) once again rejected Valeant (VRX), saying that the higher takeover bid it made in concert with Bill Ackman's hedge fund Pershing Square still "substantially undervalues the company [and] creates significant risks and uncertainties for the stockholders of Allergan." Further, Allergan said its board has "serious concerns" about the large stock component of the proposal and that the latest Valeant offer does not warrant talks between the companies. Following the latest reproach, BMO Capital said it believes the fight between the two is still in the "early innings" and could last well into 2015. Shares of Allergan slipped $1.06, or 0.65%, to $163.09, while Valeant fell $1.08, or 0.85%, to $125.55. MAJOR MOVERS: Among the notable gainers was hepatitis C treatment maker Achillion (ACHN), which surged $3.54, or 83.29%, to $7.79 after the company announced today that it had received favorable news from the FDA about resuming certain clinical trials. Achillion's advance comes on top of its 47% move higher yesterday after Merck (MRK) announced that it would acquire another company in the HCV drug space at a significant premium. Also higher was Receptos (RCPT), which jumped $10.74, or 36.78%, to $39.94 after the company reported phase 2 data for its SIPI modulator that firms Leerink and BMO Capital both viewed positively. Among the noteworthy losers was Inovio Pharmaceuticals (INO), which fell $1.44, or 13.36%, to $9.34 after TheStreet's Adam Feuerstein speculated that the company already has data in hand for its phase II study of its vaccine for cervical pre-cancerous lesions and warned of "red flags" related to the company's CEO "walking back expectations" ahead of a potential disclosure that the trial was not a success. Also lower were shares of eHealth (EHTH), which fell $5.09, or 13.05%, to $33.91 after Jefferies downgraded the stock to Hold and lowered its price target for shares to $40 from $62, citing less confidence in the company's Exchange opportunity following management comments at the firm's conference. Another stock moving lower following a downgrade was Coupons.com (COUP), which dropped $2.95, or 10.6%, to $24.88 after Goldman downgraded the shares to Sell from Neutral. INDEXES: The Dow was up 2.82, or 0.02%, to 16,945.92, the Nasdaq was up 1.75, or 0.04%, to 4,338.00, and the S&P 500 was down 0.48, or 0.02%, to 1,950.79.
News For EBAY;FB;AGN;VRX;COUP;EHTH;INO;RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
February 18, 2015
11:49 EDTFBFacebook CEO would 'love to work with Google' on connectivity, Bloomberg says
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
08:27 EDTFBFacebook in talks with media about hosting news content, Re/code says
Facebook is speaking to media publishers about hosting news content "that would otherwise go on a publisher’s own website," reports Re/code, citing statements by Facebook chief product officer Chris Cox at the Code/Media conference. Cox said Facebook could provide a larger audience and improved design, though he noted potential partnerships "aren't coming anytime soon." Additionally, Cox said the company's video efforts have been "a massive success" but the company "isn’t rushing" to pay content creators. Reference Link
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2
06:29 EDTFBFacebook engagement data remains strong, says JPMorgan
JPMorgan notes that according to comScore, Facebook’s share of mobile Internet time excluding Instagram and WhatsApp in January was 21%, up from 20% in December, and its share of total Internet time including desktop was 17%. The firm believes the data suggests continued strong engagement for Facebook. It reiterates an Overweight rating on the stock with an $85 price target, calling the stock a favorite idea for 2015.
06:10 EDTFBFacebook is developing virtual reality apps, Re/code says
Subscribe for More Information
February 17, 2015
18:17 EDTVRXJANA Partners gives quarterly update on stakes
NEW STAKES: NCR (NCR), Liberty Ventures (LVNTA), Solarcity (SCTY), Computer Sciences Corp (CSC), Salix (SLXP), and Applied Materials (AMAT). INCREASED STAKES: Hertz (HTZ), Valeant (VRX), Walgreens Boots Alliance (WBA), Rackspace (RAX), and HD Supply (HDS). DECREASED STAKES: AIG (AIG), Actavis (ACT), Charter (CHTR), AerCap (AER), and Energy Transfer Equity (ETE). LIQUIDATED STAKES: Equinix (EQIX), Cameron International (CAM), Dollar General (DG), QEP Resources (QEP), and Amgen (AMGN).
18:06 EDTAGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:18 EDTAGNPershing Square gives quarterly update on stakes
NEW STAKES: Restaurant Brands International (QSR). INCREASED STAKES: Zoetis (ZTS), and Platform Specialty Products (PAH). DECREASED STAKES: Allergan (AGN). LIQUIDATED STAKES: None.
17:13 EDTVRX, FBPoint72 gives quarterly update on stakes
Subscribe for More Information
17:06 EDTEBAYIcahn gives quarterly update on stakes, takes new stake in Manitowoc
Subscribe for More Information
17:02 EDTAGNSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
15:05 EDTFBFacebook announces official launch of Marketing Partner program
Subscribe for More Information
13:52 EDTAGNEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information
13:14 EDTFBFacebook introduces customizable product ads solution
Subscribe for More Information
10:04 EDTFBFacebook receives patent for identifying, marketing to "influencers"
Facebook has received a patent allowing it to identify "influencers" within its social network - those whose recommendations results in a significant increase of word-of-mouth and re-sharing. The patent describes a process for identifying which users are most influential, and then advertising to those specific people in order to capitalize on any potential recommendations they may make.
08:39 EDTFBMarathon Patent Group subsidiary files patent infringement suit against Facebook
Marathon Patent Group (MARA) announced that its wholly-owned subsidiary TLI Communications GmbH has filed a patent infringement lawsuit against Facebook (FB) and Facebook Ireland Limited in the Regional Court of Munich in Germany. TLI Communications is asserting infringement of the German part of European patent 0 814 611 B1 by the social media platform "Facebook" operated by the defendants, as well as the associated application software for smartphones and tablet computers.
07:22 EDTFBMitsubishi UFJ to hold a tour
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use